JMP Securities Reiterates Market Outperform on Kura Oncology, Maintains $32 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Reni Benjamin reiterated a Market Outperform rating on Kura Oncology (NASDAQ:KURA) and maintained a $32 price target.
May 06, 2024 | 3:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities reaffirmed a Market Outperform rating on Kura Oncology with a $32 price target.
The reiteration of a Market Outperform rating and a maintained price target of $32 by JMP Securities is a strong positive endorsement for Kura Oncology. This analyst backing is likely to instill confidence in investors, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100